- Home
- SVRN vs LNAI Comparison
SVRN vs LNAI Comparison
Compare SVRN & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | LNAI |
|---|---|---|
| Founded | 2021 | N/A |
| Country | Greece | United States |
| Employees | 87 | 29 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 11.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SVRN | LNAI |
|---|---|---|
| Price | $10.57 | $2.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.2K | ★ 309.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.15 |
| 52 Week High | $15.07 | $3.38 |
Technical Indicators
Market Signals| Indicator | SVRN | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 67.73 |
| Support Level | $8.16 | $0.89 |
| Resistance Level | $12.73 | $3.38 |
| Average True Range (ATR) | 1.39 | 0.34 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 62.97 | 44.70 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.